This report was recently updated on April 16 2024 with the latest and most recent
market numbers
Global Thalassemia Market Size, Trends, and Analysis - Forecasts To 2026 By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Thalassemia is a blood disease that causes a decrease in the development of generic hemoglobin, the molecule of red blood cells that carries oxygen. This leads to a lack of red blood cells and poor oxygen levels in the plasma, which can worsen the functioning of many vital organs and result in a variety of health issues. Anemias, paleness, nausea, yellow discoloration of the scalp and bone abnormalities are some of the symptoms that may occur. When an individual inherits exactly one impaired gene from both parents, the individual becomes a thalassemia carrier. Since thalassemia is a genetic condition, at least one of the parents has to be a carrier. When both those parents are carriers, the risk of having a thalassemia-affected child is incredibly significant. Thalassemia is classified into two types: alpha thalassemia and beta-thalassemia.
Inherited red blood cell diseases were once only found in the subtropics and, tropics but are now found globally owing to migration. As per the World Health Organization (WHO), thalassemia is present in 71 percent of the world's nations and 89 percent of newborns. At least 5.2 percent of the universal population and more than 7 percent of pregnant women have a major variant of thalassemia. Furthermore, at least 20% of the universal population has thalassemia. About 1.1 percent of couples globally are at a possibility of acquiring thalassemia offspring, with 2.7 in 1000 births affected. Every year, almost 56,000 babies are born with major thalassemia, with at least 30,000 requiring daily injections to live and 5,500 dying parentally. The growing number of cases of thalassemia necessitates the development of a standard treatment for the disorder, which will drive the growth of this market.
Variables such as the demand for bone marrow donation and blood transfusion therapy, as well as the large proportion of transfusion-dependent patients, and a rise in awareness of affordable care options for thalassemia are foreseen to fuel the growth of the thalassemia market. Furthermore, increasing spending on drug discovery and development, as well as stem cell therapy studies, are a couple of the drivers that are likely to support the growth of the thalassemia market throughout the forecast period. The primary goal of this sector is to advance the vaccine pipeline, increase opportunities for gene therapy, and increase awareness of thalassemia. Amidst this, there are a few variables that can stymie the overall development of the thalassemia market, including administrative changes, paired risks, and elevated treatment costs.
The global thalassemia industry is mostly influenced by factors including a rise in thalassemia individuals of all ages and a surge in global recognition of the disease. Furthermore, the continual transformation of medication pipelines and therefore the expansion of the range of approved medicine to cure thalassemia would boost the global thalassemia drug market. Additionally, increased demand for healthcare facilities in developing regions would fuel growth in the thalassemia market. While enhancing clinical trials for developing combination medications & growing research & development investment & speculation on healthcare by the governments of industrialized & emerging economies, and unmet criteria for effective therapies stimulate demand growth throughout the forecast period.
Based on the therapeutic class, the thalassemia market segment is iron-chelating drugs. Thalassemia is currently managed by symptomatic therapy rather than curing. Iron storage disease from blood transfusions, fetal hemoglobin elevating medications, vitamin supplementation, and indicaxanthin, an antioxidant that forestalls hemoglobin degradation, are among the foremost popular ailments for the disorder which are successfully treated with the help of iron-chelating drugs.
If drugs currently in phase II/III developmental pipeline gain regulatory clearance, the demand for thalassemia therapeutics is presumed to grow significantly. The demand in developing nations, including North America and Europe, is being driven by increased understanding of accessible treatment options and the implementation of new treatment approaches. Furthermore, the huge youth population in Asia Pacific's developing markets is likely to drive demand for thalassemia drugs and treatments throughout the forecast period.
Based on the Pipeline, the thalassemia market segment is gene therapy. With multiple genomic drugs in late stage testing, gene therapy is foreseen to be relatively more effective among many other potential curative treatments. Technical innovation in genome sequencing, stem cell selection, viral vector growth, transduction, and gene editing techniques now allow for effective Ex Vivo genetic modification of human stem cells, which can result in hemoglobin production, providing an improved therapeutic value to thalassemia patients. Moreover, for the prevention of thalassemia, there seem to be nearly 15 pipeline drugs undergoing drug trials. Most of those items are focused on gene therapy and aim to cure the disease. Despite major drug research problems and legal complexities, gene therapy has the ability to transform the thalassemia treatment environment.
As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). Throughout the forecast period, the North American region is presumed to dominate the thalassemia market. This is attributed to the relentless advances in technology, booming research & development efforts by main players & governments, and increasing investment by many leading players within the country. Furthermore, the growing number of thalassemia patients is estimated to drive growth within the North American region. Additionally, rising awareness of thalassemia and increasing government initiatives to promote gene therapy, as well as the advancement of the drug pipeline, are expected to drive the development of the thalassemia market in the area.
Due to the extreme severe diversity, an abnormal occurrence of thalassemia heterozygote or carrier, Asia-Pacific is presumed to see substantial development. Moreover, the government & several other organizations are trying to raise public awareness and, due to the influx of new entrants into the market, the Asia Pacific is an extremely appealing market for thalassemia therapeutics.
Acceleron Pharma, Inc., Bluebird Bio, Inc., CRISPR Therapeutics, La Jolla Pharmaceutical Company, Incyte Corporation, IONIS Pharmaceuticals, GlaxoSmithKline plc., Kiadis Pharma, Lonza Group AG, Alnylam Pharmaceuticals Inc, Sangamo Bioscience, Calimmune Inc, Gamida Cell Ltd, Editas Medicine Inc, Pharma Essentia Corp, Gilead Sciences Inc, Merck & Co Inc, Zydus Cadila Healthcare Ltd, Protagonist Therapeutics Inc, and others, are major players of thalassemia market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Thalassemia Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Therapeutic Class Overview
2.1.3 Pipeline Overview
2.1.4 Regional Overview
Chapter 3 Global Thalassemia Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Rising Prevalence of Thalassemia
3.3.1.2 Increasing Awareness of Thalassemia Treatment
3.3.2 Industry Challenges
3.3.2.1 High Cost of Treatment
3.4 Prospective Growth Scenario
3.4.1 Therapeutic Class Growth Scenario
3.4.2 Pipeline Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.7 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Thalassemia Market, By Therapeutic Class
4.1 Therapeutic Class Outlook
4.2 Iron Chelating Drugs
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Global Thalassemia Market, By Pipeline
5.1 Pipeline Outlook
5.2 Gene Therapy
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Global Thalassemia Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.2.3 Market Size, By Pipeline, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.3 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.3 Market Size, By Pipeline, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.7.2 Market size, By Pipeline, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.5.3 Market Size, By Pipeline, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.6.3 Market Size, By Pipeline, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Pipeline, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Therapeutic Class, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Pipeline, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Acceleron Pharma, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Bluebird Bio, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 CRISPR Therapeutics
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 La Jolla Pharmaceutical Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Incyte Corporation
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 IONIS Pharmaceuticals
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 GlaxoSmithKline Plc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Kiadis Pharma
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Lonza Group AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Alnylam Pharmaceuticals Inc.
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 Sangamo Bioscience
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
7.13 Calimmune Inc
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info Graphic Analysis
7.14 Gamida Cell Ltd
7.14.1 Company Overview
7.14.2 Financial Analysis
7.14.3 Strategic Positioning
7.14.4 Info Graphic Analysis
7.15 Editas Medicine Inc
7.15.1 Company Overview
7.15.2 Financial Analysis
7.15.3 Strategic Positioning
7.15.4 Info Graphic Analysis
7.16 Pharma Essentia Corp
7.16.1 Company Overview
7.16.2 Financial Analysis
7.16.3 Strategic Positioning
7.16.4 Info Graphic Analysis
7.17 Gilead Sciences Inc
7.17.1 Company Overview
7.17.2 Financial Analysis
7.17.3 Strategic Positioning
7.17.4 Info Graphic Analysis
7.18 Merck & Co Inc
7.18.1 Company Overview
7.18.2 Financial Analysis
7.18.3 Strategic Positioning
7.18.4 Info Graphic Analysis
7.19 Zydus Cadila Healthcare Ltd
7.19.1 Company Overview
7.19.2 Financial Analysis
7.19.3 Strategic Positioning
7.19.4 Info Graphic Analysis
7.20 Protagonist Therapeutics Inc
7.20.1 Company Overview
7.20.2 Financial Analysis
7.20.3 Strategic Positioning
7.20.4 Info Graphic Analysis
7.21 Other Companies
7.21.1 Company Overview
7.21.2 Financial Analysis
7.21.3 Strategic Positioning
7.21.4 Info Graphic Analysis
The Global Thalassemia Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Thalassemia Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
